Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.
AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials
BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
Alexion's Pipeline Rebuild Plan Targets Wilson's Liver Drug, More M&A Likely
Swedish target's sole product WTX101 is in Phase III trials for treating Wilson Disease. Alexion says expect more deals.
FDA Tells RegeneRx It Needs 3rd Phase III Trial On RGN-259 For Dry Eye Syndrome
The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of dry eye in a larger patient population.